Evidence-based pharmacy decisions

Run it by the sources.

Compare drugs, check interactions, pull the trials. Price across NADAC, ASP, and Medicaid FUL. Look up Part D plan formularies — tiers, PA, step therapy. Check shortages, REMS, and DEA schedule. Free for pharmacists.

Open Intelligenist → For plan fiduciaries

Continuous claim-level verification.

Your PBM hit every guarantee in the contract. Intelligenist Cortex finds the savings the contract didn’t require them to find — by checking every claim against your contract, public benchmarks, and formulary, every quarter, not once every two years.

Request the methodology memo →

From retrospective sampling to continuous claim-level verification.

Contract as the rulebook.

Generic effective rates, specialty-drug definitions, at-risk performance thresholds, rebate pass-through covenants — whatever your contract already says, evaluated against every claim row your plan adjudicates.

ii.

Independent benchmarking.

Every claim continuously validated against NADAC, ASP, Medicaid FUL, manufacturer–to–PBM rebate benchmarks, and your own contract’s definitions. Gaps quantified at line-item resolution.

iii.

Automated classification audit.

Plan-design overrides, formulary placement discrepancies, brand-to-generic reclassifications, specialty-tier gaming — detected before they distort the quarter’s spend, not two years later.

What it answers

Questions Cortex runs against your claims, your contract, and the public record.

Where does our 100% rebate pass-through deviate from manufacturer–to–PBM payment benchmarks?

Cross-references your rebate flows against industry-standard manufacturer payment ranges. Surfaces the gap that typically sits with an affiliated GPO, with the contract clause that would close it.Sources: your claims + rebate reports, public manufacturer payment ranges, your PBM contract definitions.

What share of our biosimilar-eligible adalimumab claims still went to the brand last quarter?

Counts brand vs biosimilar dispensings against your formulary’s declared preference tier, flags the override pattern, ties each override to its claim and prescriber.Sources: your claims, your formulary file, FDA Purple Book.

Is there a biosimilar for adalimumab on this patient’s plan?

The same engine, at the counter. Pulls the plan’s formulary, lists adalimumab-adbm, -atto, -bwwd with tier, PA, step therapy. Free for licensed pharmacists.Sources: plan formulary file, FDA Purple Book, manufacturer label.

Plan-level aggregate and counter-level individual, same engine. Continuous monitoring sits alongside the periodic forensic audit your firm already runs — not as a replacement, as the pre-structured claim history that makes the next forensic engagement faster and sharper. Read the full methodology →